Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma

BMC Cancer

Table 2 Correlation of nuclear EZH2 expression with clinicopathological characteristics

		Nuclear EZH2 expression
		0%		1-5%		> 5-25%		> 25-50%		> 50%
		n	%	n	%	n	%	n	%	n	%	p
Tumor extent (Robson)												*0.0071*
	Stage I	65	60	167	63	61	62	14	39	3	30
	Stage II	9	8	24	9	2	2	2	6	0	0
	Stage III	20	18	38	14	15	15	8	22	2	20
	Stage IV	15	14	37	14	21	21	12	33	5	50
Sex												0.984
	Male	67	61	161	61	63	64	23	64	6	60
	Female	42	39	105	39	36	36	13	36	4	40
Age at surgery												0.746
	< 65 years	58	53	148	56	61	62	22	61	6	60
	≥ 65 years	51	47	118	44	38	38	14	39	4	40
Karnofsky performance status scale												0.404
	≥ 80%	100	92	241	91	92	93	35	97	8	80
	< 80%	9	8	25	9	7	7	1	3	2	20
Tumor stage												*0.019*
	pT1/2	72	66	177	67	70	71	17	47	3	30
	pT3/4	37	34	89	33	29	29	19	53	7	70
Regional lymph node metastasis												*0.003*
	N0/pN0	103	95	250	94	93	94	28	78	7	70
	pN+	6	5	16	6	6	6	8	22	3	30
Distant metastasis												*0.005*
	M0	94	86	231	87	78	79	24	67	6	60
	M+	15	14	35	13	21	21	12	33	4	40
Fuhrman grade												*< 0.0001*
	G1/G2	91	83	224	85	78	80	20	56	4	40
	G3/G4	18	17	39	15	19	20	16	44	6	60
Histopathological subtype												< 0.001**
	Clear cell RCC	88	81	226	85	71	72	31	86	6	60
	Papillary (chromophilic) RCC	7	6	27	10	17	17	3	8	1	10
	Chromophobe RCC	11	10	8	3	4	4	0	0	0	0
	Duct Bellini	0	0	0	0	0	0	2	6	1	10
	Unclassified RCC	3	3	5	2	7	7	0	0	2	20
Motzer criteria (metastatic RCC, n = 51)												0.731*
	Favorable	1	11	1	6	0	0	2	20	0	0
	Intermediate	6	67	11	61	6	55	5	50	3	100
	Poor	2	22	6	33	5	45	3	30	0	0

ISSN: 1471-2407